360 High-Risk Vulnerability Immunization Tool V2.0 vs Orpheus Risk-Based Vulnerability Management: Side-by-Side Comparison (2026)

360 High-Risk Vulnerability Immunization Tool V2.0: Tool that immunizes Windows systems against critical vulnerabilities. built by 360 Security Group (Qihoo 360). Core capabilities include Remote desktop vulnerability immunization (CVE-2019-0708, CVE-2019-1181, CVE-2019-1182), MS17-010 SMB vulnerability protection against ransomware, Meltdown CPU vulnerability mitigation..

Orpheus Risk-Based Vulnerability Management: Risk-based vuln mgmt platform using ML to prioritize exploited CVEs. built by Orpheus. Core capabilities include Orpheus Vulnerability Scoring System (OVSS) for vulnerability ranking, Identification of actively exploited vulnerabilities, Exploitation prediction with up to 94% accuracy..

Both serve the Vulnerability Assessment market but differ in approach, feature depth, and target audience.

360 High-Risk Vulnerability Immunization Tool V2.0 differentiates with Remote desktop vulnerability immunization (CVE-2019-0708, CVE-2019-1181, CVE-2019-1182), MS17-010 SMB vulnerability protection against ransomware, Meltdown CPU vulnerability mitigation. Orpheus Risk-Based Vulnerability Management differentiates with Orpheus Vulnerability Scoring System (OVSS) for vulnerability ranking, Identification of actively exploited vulnerabilities, Exploitation prediction with up to 94% accuracy.

360 High-Risk Vulnerability Immunization Tool V2.0 is developed by 360 Security Group (Qihoo 360). Orpheus Risk-Based Vulnerability Management is developed by Orpheus. Vendor maturity, funding stage, and team size can be important factors when evaluating long-term viability and support quality.

360 High-Risk Vulnerability Immunization Tool V2.0 and Orpheus Risk-Based Vulnerability Management serve similar Vulnerability Assessment use cases: both are Vulnerability Assessment tools, both cover CVE, Patch Management. Review the feature comparison above to determine which fits your requirements.